New combo therapy aims to outsmart resistant breast cancer

NCT ID NCT01560416

First seen Mar 21, 2026 · Last updated May 16, 2026 · Updated 7 times

Summary

This study tested whether adding the experimental drug ganetespib to the standard hormone therapy fulvestrant works better than fulvestrant alone for people with hormone receptor-positive breast cancer that has spread. The 50 participants had cancer that was resistant to hormone therapy. The goal was to see if the combination could delay cancer growth.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02215, United States

  • DFCI at Faulkner Hospital

    Boston, Massachusetts, 02130, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • New Hampshire Oncology and Hematology, P.A.

    Concord, New Hampshire, 03301, United States

  • University of North Carolina

    Chapel Hill, North Carolina, 27599, United States

Conditions

Explore the condition pages connected to this study.